EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyseOpen Access · CC BY 4.0

Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis

Chienhsiu Huang iD, Lichen Lin iD, Sufang Kuo

Antibiotics · 23.09.2024 · 13 (9) · 907

DOI: 10.3390/antibiotics13090907 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 23.09.2024. Verfasst von Chienhsiu Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the Acinetobacter species. The effectiveness of cefoperazone/sulbactam against multiresistant Acinetobacter baumannii has not been investigated. The purpose of the current meta-analysis was to compare the efficacy of cefoperazone/sulbactam-based therapeutic regimens and non-cefoperazone/sulbactam-based therapeutic regimens in the treatment of multiresistant Acinetobacter baumannii infections. The current meta-analysis of 10 retrospective studies provides evidence that cefoperazone/sulbactam-based therapeutic regimens are superior to non-cefoperazone/sulbactam-based therapeutic regimens in terms of 30-day mortality and clinical improvement in patients with multiresistant Acinetobacter baumannii infections. The risk of mortality was reduced by 38% among multiresistant Acinetobacter baumannii infections in patients who received cefoperazone/sulbactam-based therapeutic regimens. The cefoperazone/sulbactam-based combination therapy was superior to the cefoperazone/sulbactam monotherapy in terms of 30-day mortality when both therapeutic regimens were compared to the tigecycline monotherapy in patients with multiresistant Acinetobacter baumannii infections.

Schlagwörter

Stichwörter der Autor:innen

Acinetobacter baumanniicefoperazonemortalitymultiresistantsulbactam

Autor:innen und Institutionen

  • Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
  • Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.

ORCID-Profile: Chienhsiu Huang, Lichen Lin

Zitieren

APA

Huang, C., Lin, L., & Kuo, S. (2024). Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis. Antibiotics, 13(9), 907. https://doi.org/10.3390/antibiotics13090907

Vancouver

Huang C, Lin L, Kuo S. Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis. Antibiotics. 2024;13(9):907. doi:10.3390/antibiotics13090907

BibTeX
@article{Huang2024,
  author = {Huang, Chienhsiu and Lin, Lichen and Kuo, Sufang},
  title = {Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis},
  journal = {Antibiotics},
  year = {2024},
  volume = {13},
  number = {9},
  pages = {907},
  doi = {10.3390/antibiotics13090907}
}
Kostenlos starten →